Related Experiment Videos
Pharmacogenetics in ovarian stimulation - current concepts and future options.
Robert R Greb1, Hermann M Behre, Manuela Simoni
1Muenster University Hospital, Germany. robert.greb@uni-muenster.de
Reproductive Biomedicine Online
|January 18, 2006
Summary
Genetic variations in the FSH-receptor gene influence ovarian response to stimulation. Genotyping for the p.N680S polymorphism could personalize follicle-stimulating hormone (FSH) dosing for IVF patients.
Area of Science:
- Reproductive endocrinology and pharmacogenetics.
- Investigating genetic factors influencing drug response.
Background:
- Ovarian stimulation for IVF varies significantly between individuals.
- Pharmacogenetics aims to tailor drug treatments based on genetic profiles.
- The follicle-stimulating hormone (FSH) receptor gene's role in ovarian response is under investigation.
Purpose of the Study:
- To explore the impact of the p.N680S polymorphism in the FSH-receptor gene on ovarian response to FSH stimulation.
- To assess the potential of genetic testing to individualize FSH dosing in IVF.
Main Methods:
- Review of clinical studies on FSH-receptor gene polymorphisms and ovarian response.
- Analysis of the p.N680S polymorphism's effect on FSH receptor sensitivity.
Main Results:
- The p.N680S polymorphism of the FSH-receptor gene is linked to ovarian response variability in IVF.
- Homozygous Ser(680)/Ser(680) women show reduced FSH receptor sensitivity.
Conclusions:
- Genotyping for the p.N680S polymorphism may enable personalized FSH dosing for ovarian stimulation.
- Further clinical studies are needed to validate genotyping as a routine diagnostic tool for IVF.